Virtue Diagnostics Raises $100M in Series B Funding


Virtue Diagnostics, a Singapore and Shanghai, China-based IVD company focused on infectious disease, cancer, and chronic diseases, raised $100M in Series B funding.

The round was led by Sequoia China and Morningside Ventures with participation from ORIZA Holdings, Lilly Asia Ventures, and PerkinElmer Ventures.

The company intends to use the funds to bring IVD products to selected emerging markets.

Led by Johnson Zhang, CEO, Virtue Diagnostics is a global, platform-based IVD (In Vitro Diagnostic) company focusing on providing affordable clinical solutions at all disease stages including very early screening, initial diagnosis, treatment monitoring and minimal residual disease management.

Virtue Diagnostics Corporate and R&D headquarters are in Singapore, manufacturing is in Suzhou, China and CRO/Clinical Lab is in Beijing.